HUMA Humacyte, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$1.45

Period return

+0.19 (+15.08%)

Volume

11.0M

2026-06-01O $1.3 H $1.48 L $1.29 C $1.45MA5 $1.26MA20 $1.05MA60 $0.89MA120 $0.99

6M · 124 barsYahoo Finance · USD2025-12-02 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 27.LowBUY6 days ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 14.LowBUY18 days ago
TD Cowen: Buy
US analyst rating / recommendation change.
2026. 05. 14.LowBUY19 days ago
BTIG: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $1.67 · 6 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Sector: Healthcare
Industry: Biotechnology
HQ: Durham, NC, United States
Fiscal year end: —
Employees: 184
IPO date: —

View details →

2026. 04. 29.LowBUYlast month

D. Boral Capital: Buy